We report on a 74-year-old man with a cutaneous B-cell follicle center lymphoma, which was treated upfront with systemic rituximab and suffered several local relapses. The first of the local recurrences, 10 months after completion of treatment, was characterized by a dense T-cell infiltrate that obscured a minor population of B-cell lymphoma cells, suggesting a second primary cutaneous T-cell lymphoma. This represents a previously not reported diagnostic pitfall and underscores the importance of performing sequential biopsies when dealing with lymphoma recurrences in this setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/DAD.0000000000001544 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary cutaneous/subcutaneous Ewings sarcoma.
Bull Cancer
March 2025
Pediatric Oncology, insitut Gustave-Roussy, Villejuif, France. Electronic address:
Amongst Ewing sarcoma family of tumours, (EFST), cutaneous/subcutaneous Ewing sarcoma are defined as tumours arising from cutaneous or subcutaneous tissue, not invading the underlying aponeurosis. They are rare tumours, with less than 200 patients published. They are typically small tumours (less than 5cm), and can arise at any anatomical location, with a particular tropism for distal, truncal and head/neck locations, compared to classical Ewing sarcoma.
View Article and Find Full Text PDFIn-transit melanoma metastases: Evaluation and Management for the Dermatologist.
J Am Acad Dermatol
March 2025
Mayo Clinic, Department of Dermatology, Rochester, MN, USA. Electronic address:
In-transit metastases (ITM) are estimated to occur in 5-10% of primary cutaneous melanomas. They are classified as stage III disease in the American Joint Committee on Cancer classification system and are associated with approximately a 30% 10-year survival rate. The management of ITM is not standardized.
View Article and Find Full Text PDFAssessing Total Hip Arthroplasty Outcomes and Generating an Orthopedic Research Outcome Database via a Natural Language Processing Pipeline: Development and Validation Study.
JMIR Med Inform
March 2025
LynxCare Inc, Leuven, Belgium.
Background: Processing data from electronic health records (EHRs) to build research-grade databases is a lengthy and expensive process. Modern arthroplasty practice commonly uses multiple sites of care, including clinics and ambulatory care centers. However, most private data systems prevent obtaining usable insights for clinical practice.
View Article and Find Full Text PDFClinical Characteristics, Management and Long-Term Outcomes of 180 Patients With Early-Stage Mycosis Fungoides at a Tertiary Centre-A 34-Year Retrospective Study.
Australas J Dermatol
March 2025
Department of Dermatology, Ankara University Faculty of Medicine, Ankara, Turkey.
Background: Mycosis fungoides (MF) is the commonest form of primary cutaneous T-cell lymphoma. Progression is slow, with frequent relapses. Data for predicting early-stage MF progression and recurrence are inadequate.
View Article and Find Full Text PDFImproved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types.
Cancer
March 2025
Department of Otolaryngology - Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Introduction/background: Obesity is a well-known risk factor for various cancers, yet emerging research demonstrates its association with improved survival outcomes in cancer treatment, labeled as "the obesity paradox." Studies investigating the clinical benefits of obesity across various cancer types after immune checkpoint inhibition (ICI) are limited.
Methods: Data were queried from the TriNetX database to identify patients with solid tumor malignancies of various organ systems (pulmonary/intrathoracic, cutaneous, head and neck, gastrointestinal, breast, genitourinary) who received ICI between 2012 and 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!